A Phase 2, Randomized Study of Duvelisib Administered in Combination With Rituximab vs R-CHOP in Subjects With Relapsed/Refractory Follicular Lymphoma (FRESCO)
Withdrawn prior to enrolment
Phase of Trial: Phase II
Latest Information Update: 02 Aug 2017
At a glance
- Drugs Duvelisib (Primary) ; Cyclophosphamide; Doxorubicin; Prednisone; Rituximab; Vincristine
- Indications Follicular lymphoma
- Focus Therapeutic Use
- Acronyms FRESCO
- Sponsors Infinity Pharmaceuticals; Verastem
- 28 Jul 2017 Status changed to withdrawn prior to enrolment as sponsor is focusing on studies which can enable registration of duvelisib
- 09 Jan 2017 Status changed from recruiting to discontinued.
- 27 Oct 2016 This trial was completed in Spain, according to European Clinical Trials Database.